Nordion Inc (NDZ.N)
7.49USD
19 Jun 2013
$-0.05 (-0.66%)
$7.54
$7.56
$7.59
$7.46
15,335
39,232
$10.95
$5.51
NDZ.N
About
Overall
| Beta: | 0.74 |
| Market Cap (Mil.): | $465.12 |
| Shares Outstanding (Mil.): | 61.91 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| NDZ.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 72.70 | 30.65 |
| EPS (TTM): | -0.50 | -- | -- |
| ROI: | -9.17 | 4.63 | 18.83 |
| ROE: | -12.98 | 9.75 | 19.74 |
Isotope supplier Nordion posts smaller profit
- Canadian medical isotope supplier Nordion Inc reported lower quarterly profit on Wednesday, weighed down by higher costs at two of its segments.
UPDATE 1-BTG says interventional medicine buys could boost sales to $1 bln
* Buys EKOS Corp, Nordion unit for combined initial $380 mln
BTG builds interventional medicine platform with deals
LONDON, May 23 - Britain's BTG said it would make two acquisitions, one extending its expertise in liver cancer and the other a treatment for severe blood clots, to create an interventional medicine business with potential sales of $1 billion.
Medical isotope maker Nordion's loss narrows
March 5 - Nordion Inc , a major provider of isotopes used in medical imaging, reported a smaller quarterly loss due to a gain related to the recovery of income taxes.
Hedge fund manager says Nordion should be trading at $11 a share
NEW YORK, Feb 13 - Shares of Nordion Inc should rise significantly following the company's retention last month of an adviser to consider strategic options, which could include selling all or part of the life sciences company, a New York-based hedge fund manager said on Wednesday.
UPDATE 3-Medical isotope maker Nordion explores alternatives
* Nordion suspended dividend in Sept after arbitration defeat
Nordion explores strategic alternatives
Jan 28 - Medical isotopes provider Nordion Inc said it has initiated a review of its strategic alternatives, almost four months after it suspended its dividend as an arbitration panel rejected its claim for damages from its main supplier.
Competitors
| Price | Change | |
|---|---|---|
| Quintiles Transnational (QTRN.BE) | -- | -- |
| PAREXEL International Corporation (PRXL.OQ) | $48.27 | +0.34 |
| PharmaNet Development Group Inc. (PDGI.OQ) | -- | -- |
| Covance Inc. (CVD.N) | $76.90 | -1.98 |
| Charles River Laboratories (CRL.N) | $42.14 | -0.42 |
| Covidien plc (COV.N) | $63.57 | -2.37 |
| Ion Beam Applications SA (IBA) (IBAB.BR) | €5.68 | -0.10 |
| Balchem Corporation (BCPC.OQ) | $46.12 | -0.68 |
| Agilent Technologies Inc. (A.N) | $43.52 | -1.28 |
| Becton, Dickinson and Co. (BDX.N) | $98.79 | -1.61 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Wright Reports
|
$495.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
